A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics.
Chaikuad, A., M C Tacconi, E., Zimmer, J., Liang, Y., Gray, N.S., Tarsounas, M., Knapp, S.(2014) Nat Chem Biol 10: 853-860
- PubMed: 25195011 
- DOI: https://doi.org/10.1038/nchembio.1629
- Primary Citation of Related Structures:  
4QTA, 4QTB, 4QTC, 4QTD, 4QTE - PubMed Abstract: 
Activation of the ERK pathway is a hallmark of cancer, and targeting of upstream signaling partners led to the development of approved drugs. Recently, SCH772984 has been shown to be a selective and potent ERK1/2 inhibitor. Here we report the structural mechanism for its remarkable selectivity ...